Plato Investment Management Ltd acquired a new position in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,083 shares of the medical research company’s stock, valued at approximately $907,000.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Rehmann Capital Advisory Group lifted its position in shares of Edwards Lifesciences by 2.1% during the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after purchasing an additional 130 shares during the last quarter. McIlrath & Eck LLC grew its stake in Edwards Lifesciences by 14.6% in the fourth quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock worth $90,000 after purchasing an additional 135 shares in the last quarter. Quadrant Capital Group LLC increased its holdings in Edwards Lifesciences by 0.9% in the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock valued at $1,288,000 after buying an additional 136 shares during the last quarter. Stephens Inc. AR increased its holdings in Edwards Lifesciences by 5.4% in the fourth quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company’s stock valued at $239,000 after buying an additional 144 shares during the last quarter. Finally, Composition Wealth LLC increased its holdings in Edwards Lifesciences by 1.6% in the fourth quarter. Composition Wealth LLC now owns 9,331 shares of the medical research company’s stock valued at $795,000 after buying an additional 147 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.
Edwards Lifesciences Price Performance
EW opened at $91.13 on Wednesday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The company’s 50-day moving average price is $88.90 and its 200 day moving average price is $84.49. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The firm has a market cap of $52.47 billion, a price-to-earnings ratio of 52.37, a price-to-earnings-growth ratio of 2.30 and a beta of 0.85.
Insider Buying and Selling
In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 25,570 shares of company stock valued at $2,219,390. Insiders own 0.31% of the company’s stock.
Analyst Upgrades and Downgrades
EW has been the topic of a number of research analyst reports. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Citigroup upped their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Robert W. Baird raised their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $100.27.
View Our Latest Report on Edwards Lifesciences
Edwards Lifesciences Company Profile
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Stories
- Five stocks we like better than Edwards Lifesciences
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
